Channel
Genomics, precision medicine, companion diagnostics, biopharma tools and translational research signals.
According to the latest Precedence Research report, the global biotechnology market size is expected to grow from $1.77 trillion in 2025 to $6.34 trillion by 2035, at a compound annual growth rate of 13.61%. AI-driven drug discovery, gene editing, and advanced biologics are becoming core growth engines.
The life sciences industry is accelerating its transformation toward precision medicine and AI-driven R&D. This article analyzes the latest developments of companies such as GSK, Takeda, Vertex, Novartis, Dassault Systèmes, and BMS, exploring how strategic acquisitions, regulatory approvals, and AI infrastructure are jointly shaping the new landscape of global healthcare technology.
In 2026, the biotechnology sector is moving from promise to execution. AI-driven R&D, breakthroughs in gene editing, regulatory reforms, and global transactions are reshaping the life sciences landscape. This article examines 26 key trends, covering dimensions such as scientific innovation, emerging markets, policy changes, and business models.
In 2026, the biotech and life sciences industry reaches a critical turning point. From AI-driven drug discovery to clinical breakthroughs in gene editing, from regulatory reforms to global capital flows, these 26 trends are reshaping the future of medical innovation.
Vaymed launches SKYLINE 4 and SKYLINE 6 veterinary laser therapy systems, providing advanced Class 4 laser therapy solutions for equine rehabilitation, companion animal care, and multi-species veterinary applications.
In 2026, the biotech and life sciences field reaches a critical turning point. AI and machine learning become R&D infrastructure, gene editing, synthetic biology, and microbiome therapies move toward clinical application, and global regulatory frameworks are being rapidly restructured. This article outlines 26 major trends, analyzing how technology, markets, capital, and policy are reshaping the healthcare innovation ecosystem.
The global life science tools market is being redefined by automation, data science, and precision medicine. Reports project the market will reach $455 million by 2034, with a compound annual growth rate of 10.36%.
A new report from BCG and HealthKois highlights India's rising biotech innovation but warns that structural gaps in funding, clinical execution, and regulation could limit the country's ability to scale.
Researchers developed ALADYNOULLI, a Bayesian generative framework that jointly analyzes longitudinal electronic health records, age, and polygenic risk, identifying 21 reproducible disease features and improving disease prediction performance.
Analyze how regulatory pressure, demand explosion, and drug repurposing are reshaping R&D investment strategies and the market landscape for biopharmaceutical companies.
This week's healthcare technology industry highlights: Merck KGaA acquires Bio-Techne for $11.3 billion, expanding its life science tools business; Insilico Medicine and SK Biopharmaceuticals launch a $2.5 billion AI neuroimmune drug collaboration; Anthropic introduces the Claude Science platform for antibiotic design; Nipah virus and schistosomiasis vaccines achieve clinical progress.
AbbVie acquires Apogee for nearly $11 billion, Sanofi changes leadership to address patent cliff, FDA reverses stance on gene therapy, and industry signals from BIO 2026 conference.
This week brought multiple major news in the biotechnology industry: Parabilis Medicines set a record with a $770.5 million IPO, Merck entered into a collaboration with Protillion worth up to $510 million for AI-driven drug discovery, a Lassa fever-rabies dual vaccine entered human trials, and CRISPR and mRNA delivery platforms demonstrated potential in treating cancer and Duchenne muscular dystrophy, respectively. These events reflect the accelerating convergence of capital, artificial intelligence, and gene editing technologies in medical innovation.
As GLP-1 drugs evolve from injectables to oral, multi-target, and RNA therapies, the entire metabolic disease treatment market is undergoing profound changes. This article analyzes the latest industry trends, key company strategies, and development directions over the next 3-5 years.
A recent Nature review points out that mRNA technology is moving from a vaccine tool toward a broader therapeutic platform. As bottlenecks around delivery, immune silencing, and tissue targeting are being addressed, the industry is entering the “mRNA therapeutics 2.0” phase.